|
Market Closed -
Bombay S.E.
06:02:26 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 924.70 INR | -1.88% |
|
-1.40% | -13.96% |
| Market Cap | 146B 1.54B 1.38B 1.27B 1.15B 2.15B 2.19B 15.15B 6.08B 77.04B 5.79B 5.67B 243B | P/E 2027 * |
38.4x | P/E 2028 * | 19.3x |
|---|---|---|---|---|---|
| Enterprise Value | 146B 1.54B 1.38B 1.27B 1.15B 2.15B 2.19B 15.15B 6.08B 77.04B 5.79B 5.67B 243B | EV / Sales 2027 * |
1.56x | EV / Sales 2028 * | 1.37x |
| Free-Float |
40.43% | Yield 2027 * |
0.42% | Yield 2028 * | 0.68% |
| Markets | Quality | ||
|---|---|---|---|
Bombay S.E.
| JUBLPHARMA | Delayed | |
NSE India S.E.
| JUBLPHARMA | Delayed |
Last Transcript: Jubilant Pharmova Limited
| 1 day | -1.88% | ||
| 1 week | -1.40% | ||
| Current month | -10.12% | ||
| 1 month | -10.12% | ||
| 3 months | -3.80% | ||
| 6 months | -0.22% | ||
| Current year | -13.96% |
| 1 week | 919.65 |  | 964.05 |
| 1 month | 895.25 | | 1,018.75 |
| Current year | 783.75 | | 1,106.9 |
| 1 year | 783.75 | | 1,183.9 |
| 3 years | 370.8 | | 1,309 |
| 5 years | 268.8 | | 1,309 |
| 10 years | 230 | | 1,309 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 39 | 2023-05-31 | |
| Chief Executive Officer | 50 | 2023-05-31 | |
Ashish Mukkirwar
DFI | Director of Finance/CFO | - | 2026-05-22 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 1978-07-20 | |
| Chairman | 69 | 2012-08-01 | |
| Director/Board Member | 76 | 2017-05-22 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/20/24 | Jubilant Employees Welfare Trust
| Sell | Company | 3,542 | 0.0022% | |
| 9/20/24 | Jubilant Employees Welfare Trust
| Buy | Company | 10,028 | 0.0063% | |
| 9/20/24 | Jubilant Employees Welfare Trust
| Buy | Company | 36,025 | 0.0226% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.88% | -1.40% | -17.41% | +142.35% | 1.54B | |
| +3.19% | +11.31% | +67.86% | +150.58% | 1,263B | |
| -0.73% | +3.56% | +44.51% | +85.81% | 658B | |
| +1.41% | +3.24% | +29.22% | +107.83% | 521B | |
| +0.42% | +3.20% | +54.15% | +67.18% | 391B | |
| +2.18% | +2.93% | +73.30% | +45.62% | 369B | |
| +1.12% | +4.52% | +35.30% | +58.08% | 307B | |
| +6.96% | +8.86% | +11.27% | +36.62% | 290B | |
| +1.15% | +6.09% | +59.59% | +77.06% | 252B | |
| +3.06% | +9.38% | +44.11% | +119.47% | 212B | |
| Average | +1.37% | +5.17% | +40.19% | +89.06% | 426.35B | |
| Weighted average by Cap. | +1.19% | +6.59% | +50.86% | +98.33% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 93.8B 988M 885M 814M 737M 1.38B 1.4B 9.71B 3.9B 49.34B 3.71B 3.63B 156B | 107B 1.12B 1.01B 926M 839M 1.57B 1.6B 11.05B 4.44B 56.17B 4.22B 4.13B 177B |
| Net income | 3.85B 40.51M 36.28M 33.37M 30.23M 56.52M 57.57M 398M 160M 2.02B 152M 149M 6.38B | 7.64B 80.46M 72.06M 66.29M 60.06M 112M 114M 790M 317M 4.02B 302M 296M 12.67B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-30 | ₹924.70 | -1.88% | 3,580 |
| 26-10-29 | ₹942.40 | -0.31% | 3,126 |
| 26-10-28 | ₹945.35 | -1.09% | 3,332 |
| 26-10-27 | ₹955.75 | +1.87% | 6,834 |
| 26-10-26 | ₹938.20 | +0.04% | 5,778 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- JUBLPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
